Cogent Biosciences (Cogent Biosciences) Cash-to-Debt : 14.09 (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Cogent Biosciences Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Cogent Biosciences's cash to debt ratio for the quarter that ended in Dec. 2023 was 14.09.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Cogent Biosciences could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Cogent Biosciences's Cash-to-Debt or its related term are showing as below:

COGT' s Cash-to-Debt Range Over the Past 10 Years
Min: 6.2 Med: 58.07 Max: No Debt
Current: 14.09

During the past 9 years, Cogent Biosciences's highest Cash to Debt Ratio was No Debt. The lowest was 6.20. And the median was 58.07.

COGT's Cash-to-Debt is ranked better than
60.83% of 1537 companies
in the Biotechnology industry
Industry Median: 6.49 vs COGT: 14.09

Cogent Biosciences Cash-to-Debt Historical Data

The historical data trend for Cogent Biosciences's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Cogent Biosciences Cash-to-Debt Chart

Cogent Biosciences Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

6.20

46.51

69.63

13.20

14.09

Cogent Biosciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															13.20	11.32	17.01	4.53	14.09

Competitive Comparison of Cogent Biosciences's Cash-to-Debt

For the Biotechnology subindustry, Cogent Biosciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cogent Biosciences's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cogent Biosciences's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Cogent Biosciences's Cash-to-Debt falls into.

Cogent Biosciences Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Cogent Biosciences's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	265.71	/	(1.386	+	17.467)
	=	14.09

Cogent Biosciences's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	265.71	/	(1.386	+	17.467)
	=	14.09

Cogent Biosciences (NAS:COGT) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Cogent Biosciences Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Cogent Biosciences's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Cogent Biosciences (Cogent Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cogent Biosciences Inc (NAS:COGT) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

275 Wyman Street, 3rd Floor, Waltham, MA, USA, 02451

Website

https://www.cogentbio.com

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.

Executives

Fairmount Funds Management Llc	10 percent owner, other: See Remarks	200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428
Evan Kearns	officer: Chief Legal Officer	AGENUS INC., 3 FORBES ROAK, LEXINGTON MA 02421
John L. Green	officer: Chief Financial Officer	MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
John Edward Robinson	officer: Chief Scientific Officer	C/O COGENT BIOSCIENCES, INC., 200 CAMBRIDGE PARK DRIVE, SUITE 2500, CAMBRIDGE MA 02140
Christopher W. Cain	director	2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Peter Evan Harwin	director	2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Arlene Morris	director	C/O AFFYMAX, INC., 4001 MIRANDA AVE., PALO ALTO CA 94304
Todd Shegog	director	200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139
Jessica Sachs	officer: Chief Medical Officer	C/O UNUM THERAPEUTICS INC., 200 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Matthew Ros	director	C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Karen Jean Ferrante	director	150 ADIRONDACK DRIVE, EAST GREENWICH RI 02818
Andrew R Robbins	director, officer: President and CEO	C/O 3200 WALNUT ST, BOULDER CO 80301
Venrock Healthcare Capital Partners Iii, L.p.	10 percent owner	530 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10036
Vhcp Management Iii, Llc	10 percent owner	7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Vhcp Management Ii, Llc	10 percent owner	7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018